Effects of Cannabidiol on Auditory Mismatch Negativity in Autistic Children
- 1Cognitive Neuroscience Unit, School of Psychology, Deakin University
Abstract
Pharmacological treatments targeting core autistic features remain limited. In neurotypical adults, cannabidiol (CBD) alters mismatch negativity (MMN), an electrophysiological marker of automatic auditory deviance detection that has been associated with autistic traits. The effects of CBD on MMN, as measured using electroencephalography (EEG), in autistic children remain unknown. This secondary analysis of a pilot randomised, double-blind, placebo-controlled crossover trial examined the effects of 12 weeks of oral CBD oil on MMN during a duration-deviant auditory oddball task. We hypothesised that CBD would produce more negative MMN amplitudes and shorter peak latencies relative to placebo. Nineteen autistic children (6-12 years, 8 female) received CBD (dose) and placebo in randomised order, separated by an 8-week washout. Age-adjusted linear mixed-effects models tested Time (baseline, follow-up) x Treatment (CBD, placebo) effects on mean MMN amplitude and peak latency separately at Fz and FCz. Exploratory Spearman correlations examined baseline associations between MMN and Developmental Behaviour Checklist-2 (DBC-2) Social Relating scores. At FCz, latency decreased following CBD but increased following placebo but did not survive FDR correction (p = .029, pFDR = .058) and no other interactions were significant. Higher baseline DBC-2 Social Relating scores were associated with more negative MMN amplitude at FCz ({rho} = -.58, pFDR = .028) and Fz ({rho} = -.59, pFDR = .028). These findings provide tentative evidence that CBD may modulate MMN latency in autistic children. Larger trials should clarify CBDs effects on MMN and further examine the association between MMN amplitude and social-relating difficulties.
Related
- A Strength‑Based Neurodiversity‑Affirming Investigation of Digital Interventions for Autistic Children in China: Multi‑Perspective Thematic Analysis With Parents and Therapists
- A Critical Review of Caregiver Report Measures of Autistic Traits in Children (4 to 12 years): Considerations for Research and Clinical Practice
- Exploring the Utility of the Quick Interactive Language Screener in Young Autistic Children
- Experiences of telehealth-delivered occupational performance coaching among Palestinian mothers of autistic children: a qualitative study.
- Music therapy and music-based support for autistic children: a neurodiversity-informed systematic review and meta-analysis
BibTeX
@misc{budhiraja2026effects,
title = {{Effects of Cannabidiol on Auditory Mismatch Negativity in Autistic Children}},
author = {K. Budhiraja and N.-F. Parrella and A. T. Hill and S. Catchlove and L. A. Downey and P. G. Enticott and T. C. Ford},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.14.26365371},
url = {https://www.medrxiv.org/content/10.64898/2026.10.14.26365371v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Effects of Cannabidiol on Auditory Mismatch Negativity in Autistic Children
AU - K. Budhiraja
AU - N.-F. Parrella
AU - A. T. Hill
AU - S. Catchlove
AU - L. A. Downey
AU - P. G. Enticott
AU - T. C. Ford
PY - 2026
DA - 2026/10/14
PB - medRxiv
DO - 10.64898/2026.10.14.26365371
UR - https://www.medrxiv.org/content/10.64898/2026.10.14.26365371v1
AB - Pharmacological treatments targeting core autistic features remain limited. In neurotypical adults, cannabidiol (CBD) alters mismatch negativity (MMN), an electrophysiological marker of automatic auditory deviance detection that has been associated with autistic traits. The effects of CBD on MMN, as measured using electroencephalography (EEG), in autistic children remain unknown. This secondary analysis of a pilot randomised, double-blind, placebo-controlled crossover trial examined the effects of 12 weeks of oral CBD oil on MMN during a duration-deviant auditory oddball task. We hypothesised that CBD would produce more negative MMN amplitudes and shorter peak latencies relative to placebo. Nineteen autistic children (6-12 years, 8 female) received CBD (dose) and placebo in randomised order, separated by an 8-week washout. Age-adjusted linear mixed-effects models tested Time (baseline, follow-up) x Treatment (CBD, placebo) effects on mean MMN amplitude and peak latency separately at Fz and FCz. Exploratory Spearman correlations examined baseline associations between MMN and Developmental Behaviour Checklist-2 (DBC-2) Social Relating scores. At FCz, latency decreased following CBD but increased following placebo but did not survive FDR correction (p = .029, pFDR = .058) and no other interactions were significant. Higher baseline DBC-2 Social Relating scores were associated with more negative MMN amplitude at FCz ({rho} = -.58, pFDR = .028) and Fz ({rho} = -.59, pFDR = .028). These findings provide tentative evidence that CBD may modulate MMN latency in autistic children. Larger trials should clarify CBDs effects on MMN and further examine the association between MMN amplitude and social-relating difficulties.
ER -